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Abstract
Introduction: SARS-CoV-2 is the etiologic agent of Coronavirus Disease 2019 (COVID-19), a highly contagious, emergent, acute, viral pneumonia that emanated sporadically
in Wuhan, China, in December 2019. COVID-19 became
a pandemic in February 2020, leading to 4,942,687 confirmed cases and over 321,987 deaths and grounding several economies around the world as of May 2020. Although
global researchers, epidemiologists, virologists, and medical
professionals rose steadily to contain the disease, in-depth
knowledge of the virus and concerted efforts to combat it
are still evolving. This research sought to elucidate the biological Strengths, Weaknesses, Opportunities, and Threats
to SARS-CoV-2, with a view to understanding and devising holistic strategies to combat, mitigate, and overcome the
scourge of COVID-19.
Methods: This narrative review utilized PubMed, Google,
the Directory of Open Access Journals, ProMed, and other
databases to search for and finally select 98 publications
on coronaviruses, 2019-nCoV, and COVID-19 disease, using text word searches to generate the specific search terms.
Relevant publications were reviewed and compared; findings
were synthesized using a narrative method and presented
qualitatively.
Results: Some identified Strengths of SARS-CoV-2 include:
the virus has the ability to effectively cross the species barrier
and establish productive infection in humans; SARS-CoV-2
is a new strain of coronavirus; three virulence factors (Nsp1,
Nsp3c and ORF7a) interfere with the host’s innate immunity
and immune escape; ORF8 and ORF10 proteins are uniquely
associated with SARS-CoV-2; the genetic fitness of the spike
protein facilitates attachment and fusion; a polybasic cleavage site exists in the genome; SARS-CoV-2 has a short serial interval of 4.0 days; the virus has the ability to resurge and
enter into regular circulation after the initial pandemic wave.
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The Weaknesses include: angiotensin-converting enzyme 2
(ACE2) is the sole receptor for SARS-CoV-2; host protease
processing during viral entry is a significant barrier for several
lineage β-coronaviruses; SARS-CoV-2 critically requires porphyrin to inhibit human heme metabolism. The Opportunities
harnessed by SARS-CoV-2 include: host cellular receptors
for SARS-CoV-2 infection are expressed by several important organs in the human body; ease of travel, globalization,
and aviation are potential avenues for global spread; underlying illnesses, older age, male gender, smoking, and immunosuppression increase vulnerability; knowledge is still evolving
on the underlying pathogenic mechanisms of SARS-CoV-2;
there is potential for silent transmission via blood and blood
products; there is no approved COVID-19 vaccine; the virus
is associated with a confounding pattern of signs and symptoms, as well a disproportionate “cytokine storm” or damaging
evolution of effective defenses. The Threats to SARS-CoV-2
include: prohibition of mass gatherings; prompt hospitalization, isolation, and quarantining of infected individuals; repurposing proven antimalarial/antiviral/anti-inflammatory drugs;
deployment of rapid laboratory equipment and procedures for
prompt detection; potential antiviral activities of coagulation
factors Xa and IIa (thrombin) and convalescent plasma; elucidation of the genome sequences; and global COVID-19 research funding.
Conclusion: SARS-CoV-2 capitalizes on its biological
strengths, conserves its weaknesses, and exploits the host
opportunities to decimate human populations. For interventions to overcome the virus and end the COVID-19 pandemic,
research scientists, academia, funders, industry, healthcare
professionals, and the citizenry should scale up all promising research by strategically focusing on decreasing the
Strengths and Opportunities, while capitalizing on the Weaknesses of and Threats to the virus.

1

ULJRI
Introduction
In December 2019, a cluster of human pneumonia of
unknown etiology that emanated post-infection from
a Wuhan seafood market was found in patients with
respiratory distress in Wuhan, China, and was first described by Dr. Li Wenliang, an ophthamologist who
eventually contracted 2019-nCoV from his glaucoma
patient and died of COVID-19 at the Wuhan Central Hospital.[1, 2] This resulted in an outbreak, and
the pathogen was subsequently identified as a human
coronavirus that was provisionally named the “2019
novel coronavirus” (2019-nCoV) by the World Health
Organization (WHO) on January 7, 2020. The WHO’s
Emergency Committee declared the 2019-nCoV outbreak to be a public health emergency of international
concern (PHEIC) on January 30, 2020.[3] Following the
criteria of International Committee on Taxonomy of
Viruses (ICTV) for naming newly discovered viruses,
the etiology of the pneumonia was renamed as “severe acute respiratory syndrome coronavirus 2” (SARSCoV-2) on February 11, 2020, while the associated disease was named by the WHO as coronavirus disease
2019 (COVID-19).[4] COVID-19 is an acutely fatal respiratory illness caused by SARS-CoV-2, a strain of severe acute respiratory syndrome–related coronavirus,
characterized predominantly by high fever, harsh dry
cough, difficulty breathing, and fatigue. Other less
commonly reported symptoms include body aches,
joint pains, skin tingling, loss of smell, metallic taste,
diarrhea, septic shock, coma, and death within three
weeks of infection. SARS-CoV-2 has been moderately
successful in penetrating the human species because
of its virulence and low fatality rate (2–3%) compared
to the Middle East respiratory syndrome coronavirus
(MERS-CoV), which had a 35% case fatality.[5] The majority of initial cases of COVID-19 were epidemiologically linked to exposure to Wuhan’s Huanan seafood
market, where wild animals are traded.[6] Subsequent
phylogenetic data implicated a zoonotic origin, and
the ongoing rapid spread suggests person-to-person
transmission in human populations. As of May 19,
2020 (17:27 GMT+1), statistics from 213 countries and
territories and 2 international conveyances indicated
that there were 4,942,687 confirmed cases of COVID-19
around the world. Out of the currently active 2,684,199
infected patients, 2,639,039 (98%) were in mild condition, while 45,160 (2%) were in critical condition. Of the
2,258,488 closed cases, 1,936,501 (86%) have recovered
and been discharged while 321,987 (14%) have died.[7]
Nomenclature and taxonomy of SARS-CoV-2
For an outbreak of a new viral disease, there are three
names to be decided: the disease (by the WHO), the
virus (by expert virologists), and the species (by the
ICTV). Based on phylogeny, taxonomy, and established
practice, the coronavirus study group of the ICTV recognizes this virus as forming a sister clade to the pro-
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totype human and bat severe acute respiratory syndrome coronaviruses (SARS-CoVs) of the species severe
acute respiratory syndrome-related coronavirus and designates it “SARS-CoV-2”.[8] In the realm Riboviria, the
emergent SARS-CoV-2, like all other coronaviruses, is
an RNA virus belonging to the order Nidovirales, suborder Cornidovirineae, family Coronaviridae, and subfamily Coronavirinae. This subfamily includes four
genera, namely Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. Both SARS-CoV2 and SARS-CoV are in the genus Betacoronavirus.[6]
The genome of SARS-CoV-2 is more than 85% similar
to the genome of the SARS-like virus ZC45 (bat-SLCoVZC45), and together, these viruses form a unique
Orthocoronavirinae subfamily with another SARS-like
virus, ZXC21, in the subgenus Sarbecovirus (lineage B)
that shows typical Betacoronavirus gene structure.[8, 9]
Among the original SARS-CoV coronaviruses currently
known to infect humans, the new SARS-CoV-2 (identified in 2020) is the seventh strain after HCoV-OC43 and
HCoV-229E (both detected in 1960s), SARS-CoV (identified in 2003), HCoV-NL63 (identified in 2004), HCoVHKU1(identified in 2005), and MERS-CoV (identified
in 2012).[10, 11] Based on individual specific isolate,
SARS-CoV-2 may be named, for example, SARS-CoV2/human/Wuhan/X1/2019.
In morphology, SARS-CoV-2, like SARS-CoV and
MERS-CoV, derived its name from the crown-like
(“corona” means crown in Latin) appearance that the
glycoprotein spikes form on the surface of the virus
particle. SARS-CoV-2 is an enveloped virus with RNA
genome whose virion is morphologically round or elliptic and often pleomorphic with a diameter of approximately 50–200 nm. The linear, positive-sense,
single-stranded RNA genome (belonging to Class IV of
the David Baltimore classification system and a property that may explain its fast replication) has 10 open
reading frames and contains 29,891 nucleotides, encoding 9860 amino acids (Figure 1). NSP1 to NSP11 are encoded in ORF1a, and NSP12 to NSP16 are encoded in
ORF1b. ORF1a and ORF1b generate multiple nonstructural proteins (such as 3-chymotrypsin-like protease,
papain-like protease, helicase, and RNA-dependent
RNA polymerase) upon protease cleavage.[12, 13] The
replicase proteins are involved in transcription and
replication of viral RNAs. ORF2-10 encodes four viral
structural proteins, comprising the spike glycoprotein
(S), envelope (E), membrane (M), and nucleocapsid (N)
and accessory proteins. The nucleocapsid encapsidates
the RNA genome while the spike, envelope, and membrane proteins are uniquely involved in the formation
of the viral coat/envelope.
Strengths, Weaknesses, Opportunities, and Threats (SWOT)
A SWOT analysis is usually represented as a grid,
called a 2×2 contingency table. It is a business or strategic planning technique used to summarize the key
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Figure 1. Morphology of SARS-CoV-2.[13] © 2021, StatPearls Publishing LLC; figure contributed by Rohan Bir Singh, MD. This is an openaccess publication distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). No changes were made to this figure.

components of the strategic environments. The technique is credited to Albert Humphrey at Stanford University between the 1960s and 70s, who led a research
project that involved 5,000 interviews, was funded by
fortune 500 companies, and took 9 years to develop.[14]
SWOT is a widely used framework for organizing and
using data and information gained from situation analysis. The technique enables a group or individual to
move from everyday problems or traditional strategies to a fresh perspective. It generally is a framework for identifying and analyzing the internal and
external factors that can have an impact on the viability of a project, product, government, place, organism,
or person. The SWOT concept is an assessment technique originally developed for business and industry
with a long track-record of effectiveness, equally useful in other areas, and applicable to a variety of levels
of operation.[15] The benefits of SWOT include identification of areas of strengths and weaknesses, provision of comprehensive overview for contingency planning, and development of a “plan of action” to act on
in a snapshot. SWOT analysis might be used to explore
possibilities for new efforts or solutions to problems or
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to make decisions about the best path for an initiative
and is an excellent way to organize derived information
from studies or surveys. SWOT is typically applied in
a positive connotation but could be applied to the examination of SARS-CoV-2 and how it could be more
pathogenic and more communicable. The multiplicitous effects of the COVID-19 pandemic are turning tables and fast-tracking global economies into recession
with attendant attenuation of several human activities,
such as education, religious activities, tourism, finance,
governance, business, socialization, employment, technology, healthcare programmes, and sports. Therefore,
urgent enduring interventions are required to stop the
pandemic.
The objectives of this innovative review were to
adapt the SWOT concept to: identifying the biological strengths of SARS-CoV-2, determining the weaknesses of SARS-CoV-2, identifying the opportunities
harnessed by SARS-CoV-2, determining the threats to
SARS-CoV-2, identifying gaps where scientists and researchers could key in for productive research, and encouraging scientists, researchers, patients, nations, industry, and academia to explore this paradigm shift
3
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Figure 2. Flow diagram of literature searches for the SWOT Analysis of SARS-CoV-2.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/45

4

ULJRI
for holistic knowledge in combating the recalcitrant
emerging SARS-CoV-2.

Methods
Databases used in this study included: Medline,
PubMed, DOAJ, BIOSIS Previews, medRxiv, JAMA
network, JohnsHopkinsCSSE, the WHO and CDC websites, the COVID-19 Resource center, and the Google
search engine. Text word searches (including “wildcards” to capture term variations, e.g., SWOT analysis, COVID-19, 2019-nCoV, SARS-CoV-2, SARS, Pathophysiology, diagnosis, zoonotic disease, biological
strengths of SARS-CoV-2, weaknesses of SARS-CoV-2,
opportunities harnessed by 2019-nCoV, SARS pneumonia outbreak in China, threats to 2019-nCoV, viral pneumonia, and multiorgan failure due to viral pneumonia)
were conducted using keywords pertaining to 2019nCoV, COVID-19 and pangolins, coronaviruses, bushmeat trade, bat-associated zoonoses, and the urban environment. Groups of key words were combined using
boolean operators. Medline was searched using Medical Subject Headings (natural reservoir, horseshoe bats,
zoonoses, COVID-19, Coronaviruses, 2019-nCoV pneumonia outbreaks) in various combinations. The literature search was conducted between January and April
2020. A total of 140 articles were identified/selected for
consideration (Figure 2). To ensure that the review was
focused on the most up-to-date researches, all papers
published prior to 1970 and in languages other than
English, Chinese and French were excluded (n=20). Remaining papers (n=120) were organized for inclusion
and reviewed according to the amount of information
that they contributed regarding the ecology, transmission, strengths, weaknesses, opportunities, and threats
of SARS-CoV-2 pathogen associated with humans. Articles with significant ecologic content were retained
(n=100) and other articles were also included considering the importance of the virus and information obtained (n=5). Finally, articles not focused on human
Coronaviruses or SARS-CoV-2 outbreak and transmission around the world from human to human or from
bats in urban centers were excluded (n=15). Additional
sources (n=8) were added through citation searching
and to fill specific information gaps. A total of 98 papers were reviewed in detail, data from these papers
were extracted and synthesized based on the methodology for narrative synthesis as described.[16] The goal
of narrative synthesis is to identify common themes
across research regarding a particular subject that then
can be used to identify commonalities and critical differences among included articles.

SWOT Analysis of SARS-CoV-2

Results and Discussion
Strengths of the Severe Acute Respiratory Syndrome Coronavirus 2
Strengths are the characteristics of SARS-CoV-2 that
confer the pathogen advantages over the host and other
diseases. They comprise the positive tangible and intangible attributes internal to SARS-CoV-2. Essentially,
the biological strengths and attributes (Table 1) that facilitate the pathogenicity, establishment, and spread of
the SARS-CoV-2 include the following.
Ability to effectively cross the species barrier and establish productive infection in humans: The species
barriers separating humans from nonhuman animal
species represent a major challenge for effective exposure to, infection by, and subsequent spread of zoonotic
pathogens among humans.[17] These species barriers can be divided into three largely complementary
sets. First, the interspecies barrier, which determines
the nature and level of human exposure to zoonotic
pathogens. Second, the intrahuman barrier, which determines the ability of zoonotic pathogens to productively infect a human host and effectively cope with
the immune response. Third, the interhuman barrier,
which determines the ability of zoonotic pathogens to
efficiently transmit among humans, causing outbreaks,
epidemics, or pandemics. Only the zoonotic pathogens
that cross the three barriers have the potential to sustainably establish themselves in the human population.[18] Coronaviruses primarily cause enzootic infections in birds and mammals but, in the last few
decades, have proven to be capable of infecting humans as well. The outbreaks of SARS in 2003 and, more
recently, MERS have demonstrated the lethality of coronaviruses when they cross the species barrier and infect
humans. The emergent novel SARS-CoV-2 has successfully crossed to humans from animal species, causing
the pandemic of COVID-19. Identifying the factors that
allow SARS-CoV-2 to cross each of these three sets of
barriers is essential to mitigate burdens of COVID-19.
In addition, intensive domestic animal breeding facilitates viral mixing and increased targets for spillover
from wild viruses.[19] In the current epidemic, pet dogs
and cats, ferrets, and tigers in zoos have been identified, so far, as animals infected with SARS-CoV-2,
thereby increasing the host range and potential reservoirs. These findings emphasize probable human to animal and animal to human transmissions. Contrary to
SARS-CoV-2, one of the factors that led to the scientific
success in the eradication of smallpox was the inability of the pox virus to cross the species barrier, thereby
limiting it to productive infection only in a susceptible
single host (i.e., humans).[20, 21]
SARS-CoV-2 is a new strain of coronavirus: SARSCoV-2 is a new strain of coronavirus not previously
identified in humans. As a new virus, nobody has
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Table 1. Contingency Table (2 by 2) of SWOT Analysis of SARS-CoV-2.

Helpful to SARS-CoV-2 in achieving pathogenic
objective (decrease)

Harmful SARS-CoV-2 in achieving pathogenic
objective (increase)

Strengths
Internal
factors
(i) Ability to effectively cross the species barrier
(attributes of
and establish productive infection in humans.
SARS-CoV-2)
(ii) SARS-CoV-2 is a new strain of coronavirus.
(iii) Natural reservoir of SARS-CoV-2 is unconfirmed.
(iv) Three virulence factors (Nsp1, Nsp3c and
ORF7a).
(v) Interferes with host’s innate immunity and escape.
(vi) ORF8 and ORF10 proteins are uniquely associated with SARS-CoV-2.
(vii) SARS-CoV-2 is highly infectious at very low
levels and has a short incubation period.
(viii) Genetic fitness of the spike protein facilitates
attachment and fusion.
(ix) Existence of polybasic cleavage site in the
genome.
(x) SARS-CoV-2 elicits myocardial injury and
multiorgan failure.
(xi) SARS-CoV-2 primarily targets the anatomical vulnerability of the lungs.
(xii) Permissiveness of the oral cavity for infection and possibility of virus transmission via
saliva.
(xiii) SARS-CoV-2 has a short serial interval of 4
days.
(xiv) SARS-CoV-2 is very stable on most surfaces.
(xv) Ability to resurge and enter into regular circulation after the initial pandemic wave.
(xvi) SARS-CoV-2 evolves in vivo after infection,
promoting virulence, infectivity, etc.

Weaknesses

External
factors

Threats

Opportunities
(i) Host cellular receptors for SARS-CoV-2 infection are expressed by several important
organs in human body.
(ii) Ease of travel, globalization, and aviation as
potentials for global spread.
(iii) Underlying illnesses, age, gender, smoking,
and immune suppression are risk factors.
(iv) Rumors and misinformation about origin.
(v) Knowledge is yet evolving on the underlying
pathogenic mechanisms of SARS-CoV-2.
(vi) Potential silent transmission via blood and
blood products.
(vii) No approved COVID-19 vaccine.
(viii) Low sensitivity of upper respiratory specimens for detection of SARS-CoV-2.
(ix) Confounding pattern of signs and symptoms.
(x) Disproportionate “cytokine storm” or damaging evolution of effective defenses.
(xi) Potential transmission via fecal-oral route.
(xii) Collection, consumption, and trade of wild
game.
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(i) Angiotensin-converting enzyme 2 (ACE2) is
the sole receptor for SARS-CoV-2.
(ii) Host protease processing during viral entry
is a significant barrier for several lineage B
viruses.
(iii) Low basic reproduction number (R0 ) of 3.8.
(iv) SARS-CoV-2 critically requires porphyrin to
inhibit human heme metabolism.

(i) Prohibition of mass gatherings, prompt hospitalization, isolation, and quarantine of infected individual.
(ii) Prohibition of all wildlife trade to effectively
prevent viral prevalence.
(iii) Repurposing
proven
antimalarial/antiviral/anti-inflammatory
drugs.
(iv) Deployment of rapid laboratory equipment
and procedures for prompt detection (ELISA,
Western Blot, PCR).
(v) Active contact tracing and monitoring.
(vi) Appropriate burial practices according to international best practices.
(vii) Sterilization or disinfection of equipment and
safe disposal of waste.
(viii) Potential antiviral activities of coagulation
factor Xa, IIa (thrombin), and convalescent
plasma.
(ix) Availability of the genome sequences.
(x) Global COVID-19 research funding.
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Figure 3. Transmission cycle of SARS-CoV-2.[13] © 2021, StatPearls Publishing LLC; figure contributed by Rohan Bir Singh, MD. This is an
open-access publication distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). No changes were made to this
figure.

prior immunity to SARS-CoV-2 infection. This theoretically means that the entire human population is potentially susceptible to SARS-CoV-2 infection. Immunological memories to infections are important in immune
responses. Therefore, recruitment of memory T-cells
is lacking in SARS-CoV-2 exposure-naive individuals.
Although development of antibodies (seroconversion)
was found after 7 days in 50% of patients (14 days in
all), it was not followed by a rapid decline in viral
load.[22] This empowers the virus to deride the host
prior to the emergence of any protective antibody. Yet,
despite the high homology of bat Coronavirus RaTG13
and SARS-CoV-2 in spike sequences, a recent report
found that four among the five most important amino
acids (L465, L495, Y502, D510, and H514) that bind
to ACE2 in Bat-CoV RaTG13 differ from SARS-CoV2.[23] Furthermore, there is no related research literature to date about whether Bat-CoV RaTG13 can infect
humans, making the SARS-COV-2 a unique virus.
Natural reservoir of SARS-CoV-2 is unconfirmed:
The natural reservoir of a pathogen is the natural host
that harbors the pathogen and in which it replicates
without any clinical manifestation of the disease. The
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exact origin, locations, and natural habitat (known as
the “natural reservoir”) of SARS-CoV-2 remain unconfirmed. Recently, it was reported that the sequence similarity between SARS-CoV-2 and the coronavirus isolated from Rhinolophus affinis was 96.2%, suggesting
that bats may be the source of the virus (Figure 3). Further data indicated that the intermediate host between
bats and humans was a pangolin (Manis pentadactyla,
a scaly anteater), an endangered and commonly trafficked mammal, in which genetic recombination or reassortment of the bat and pangolin coronaviruses could
have occurred.[24, 25] This was corroborated on February 7, 2020, as it was announced that nucleic acid sequences from a pangolin sample shared 99% similarity
with the pandemic human SARS-CoV-2 strain.[26]
Three virulence factors (Nsp1, Nsp3c and ORF7a)
interfere with the host’s innate immunity and assist SARS-CoV-2 immune escape: In coronaviruses,
Nsp1 interacts with the host 40S ribosomal subunit
that induces specifically host mRNA degradation and
also inhibits type-I interferon production.[27] Nsp3c
has the ability to bind with the host’s ADP-ribose to
help the coronavirus resist host innate immunity.[28]
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Research shows that bone marrow matrix antigen 2
(BST-2) can inhibit the release of newly assembled coronavirus from host cells while SARS-CoV ORF7a directly binds to BST-2 and inhibits its activity by blocking the glycosylation of BST-2.[29] Consequently, the
trajectory of this evidence suggests that Nsp1, Nsp3c
and ORF7a may be potential targets for anti-viral drug
discovery.
ORF8 and ORF10 proteins are uniquely associated
with SARS-CoV-2: The ORF3b, ORF8, and ORF10
proteins have no homology proteins in SARS-CoVs.
They may play a bigger role in the infectivity and
pathogenicity of SARS-CoV-2.[30]
SARS-CoV-2 is highly infectious at very low doses
and has a short incubation period: COVID-19
spreads through close contact, by direct inhalation of
droplet nuclei (containing SARS-CoV-2 virions) that
are released when the infected coughs, speaks, yawns,
sneezes, or breathes (although the virus may become
airborne). Susceptible individuals may also pick up
the virus from contaminated surfaces and then inadvertently inoculate the mucosal membranes of the eyes,
nostrils, mouth, and possibly other orifices (ear, anus,
urethra) of the body. About 10,100 pfu of the virus is
sufficient for infection, and the time interval from infection with the virus to the onset of symptoms is 1–14
days, but more often within 3–5 days.[31]
Genetic fitness of the spike protein facilitates attachment and fusion: The critical SARS-CoV-2 spike glycoprotein S is responsible for virus binding and entry. Whether through natural or genetic engineering,
the spike protein has been well modified to latch on
to human ACE2 enzymes for attachment. Research
shows that the receptor binding domain of the spike
glycoprotein of pangolin-coronavirus was found to be
virtually identical to the SARS-CoV-2 strain, with one
amino acid difference as a result of mutation.[32] The
S precursor protein of SARS-CoV-2 can be proteolytically cleaved into S1 (685 aa) and S2 (588 aa) subunits.
The S1 protein of 2019-nCoV shares about 70% identity
with that of human SARS-CoVs while the S2 protein
is well conserved among SARS-CoV-2 strains.[33] The
highest number of variations of amino acids in the receptor binding domain is located in the external subdomain, which is responsible for the effective direct interaction between the virus and host receptor.[26]
Existence of polybasic cleavage site in the genome:
The incorporation of a polybasic cleavage site (RRAR)
that enhances pathogenicity makes the SARS-CoV2 unique among known ‘lineage B’ beta coronaviruses.[34] SARS-CoV-2 spike glycoprotein harbors a
furin cleavage site at the boundary between the S1/S2
subunits, which is processed during biosynthesis. The
presence of a furin cleavage site sets SARS-CoV-2’s
spike apart from SARS-CoV and SARS-related coron-
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aviruses that possess a monobasic S1/S2 cleavage site.
This site allows effective cleavage by furin and other
proteases and has a role in determining viral infectivity
and host range.[35] In addition, a leading proline inserted at this site in SARS-CoV-2 (PRRA) is predicted to
result in the addition of O-linked glycans to S673, T678,
and S686, which flank the cleavage site and are unique
to SARS-CoV-2, thereby impacting the transmissibility
and pathogenesis, such as is obtained in the HA spike
of avian influenza viruses.[36, 37] The function of the
predicted O-linked glycans could create a “mucin-like
domain” that shields epitopes or key residues on the
spike protein of SARS-CoV-2 such as in HIV, thereby
utilizing glycan shields in immune evasion.[38]
SARS-CoV-2 elicits myocardial injury and multiorgan failure: Initial symptom of COVID-19 in some
patients include cardiovascular presentation such as
heart palpitations, tightness in the chest without respiratory symptoms. Increased cardiac troponin (>28
pg/mL), higher blood pressure (145 mm Hg) and increased creatinine kinase were often recorded as indications of heart injury.[39] Scientists have found that
chest computer tomography (CT) scan had high sensitivity for diagnosis of COVID-19. PCR testing sensitivity may be as low as 60-70%.[39] Patients may have
pneumonia and CT abnormalities but be initially PCR
negative while peripheral focal or multifocal groundglass opacities affecting both lungs may be observed in
up to 75% of patients during the early course of the disease.[39, 40] As ACE2, a type I membrane protein is hijacked by SARS-CoV-2, the primary physiological role
in the maturation of angiotensin (Ang), a peptide hormone that controls vasoconstriction and blood pressure
is attenuated.[41] Consequently, decreased expression
of ACE2 is associated with cardiovascular diseases.
SARS-CoV-2 infection and enrichment of ACE2 expression in cholangiocytes (hepatobiliary system) was proposed to potentially lead to direct damage of intrahepatic bile ducts and in COVID-19 patients, mild to moderate liver injury were often reported with elevated
aminotransferases, hypoproteinemia and prothrombin
time prolongation, in up to 60% of patients.[41, 42]
SARS-CoV-2 primarily targets the anatomical vulnerability of the lungs: The original SARS virus displays less affinity for ACE2 compared to SARS-CoV-2
which has a higher tropism for the highly expressed
human ACE2 in the mucous membrane of the alveolar
epithelial cells of the lungs (Type II pneumocytes). The
spongy nature of the lungs and cell-to-cell fusion of the
pneumocytes upon infection, leads to the pathological
cellular syncytial formation, fibrosis, symptomatic asphyxiation, hypoxemia, alveolar edema, or pulmonary
congestion owing to fluid accumulation and drowning
feeling experienced by severe patients.[43, 44]
SARS-CoV-2 has a short serial interval of 4.0 days:
Serial interval indicates how long it takes one infected
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person at a particular stage of the disease to infect another person to the point of the same stage of the disease. To epidemiologists, the serial interval is the second most important number. The serial interval suggests how rapidly the disease can spread, which in turn
determines whether public health officials can identify
and quarantine all known contacts of an infected individual. Although the (R0 ) of SARSCoV-2 is known,
the median serial interval of 4.0 days appears to be
short.[45] meaning that the virus has the potential to
spread faster, as being witnessed in the current pandemic. The incubation-period distribution of SARSCoV-2 is 5.0 days.[31, 46] This is higher than the serialinterval, meaning that the infected have started transmitting the virus at pre-symptomatic stage, which consequently makes contact tracing and quarantining difficult.
Permissiveness of the oral cavity for infection and
ability of virus transmission via saliva: ACE2 receptors are present and highly enriched in epithelial cells
of the tongue, suggesting potentiality of infectious susceptibility of the oral cavity.[47] Similarly, SARS-CoV-2
sequences were reportedly detected in saliva thereby
indicating replication in the salivary glands.[30] This
portends the potentials of saliva as a vehicle of transmission from asymptomatic cases via dental care, sexual contacts, sharing feeding utensils and spitting.
SARS-CoV-2 is very stable on most surfaces compared to other respiratory viruses: For a respiratory
virus to perpetually transmit, it is required that the
virus particles remain viable and stable in air and on
surfaces long enough after expulsion from the host to
be taken up by a fresh susceptible host. The median
half-life estimate for SARS-CoV-2 is around 13 hours
on steel and around 16 hours on polypropylene. Viable virus could be detected in aerosols up to 3 hours
post aerosolization, up to 4 hours on copper, up to 24
hours on cardboard and up to 2-3 days on plastic and
stainless steel indicating that SARS-CoV-2 shows relatively long viability on stainless steel and polypropylene compared to copper or cardboard.[48] These show
that aerosol and fomite transmission of COVID-19 is
plausible, as the virus can remain viable in aerosols for
multiple hours and on surfaces up to days.
Ability to resurge and enter into regular circulation
after the initial pandemic wave: Mathematical modeling was used to predict the transmissibility dynamics of SARS-CoV-2. Using a two-strain ordinary differential equation (ODE), susceptible-exposed-infectiousrecovered (SEIR) compartmental model, and maximum
likelihood parameter values, transmission of HCoVOC43, HCoV-HKU1 and SARS-CoV-2 were simulated
for sustained transmission. Model simulations demonstrated that:
1. SARS-CoV-2 can proliferate at any time of year.
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2. If immunity to SARS-CoV-2 is not permanent, it
will likely enter into regular circulation much like
pandemic influenza, possibly in annual, biennial, or
sporadic patterns over the next five years.
3. Short-term immunity (40 weeks, similar to HCoVOC43 and HCoV-HKU1) favors the establishment
of annual SARS-CoV-2 outbreaks, while longer-term
immunity (two years) favors biennial outbreaks.
4. If immunity to SARS-CoV-2 is permanent, the virus
could disappear for five or more years after causing a major outbreak. If SARS-CoV-2 induces cross
immunity (70%) against HCoV-OC43 and HCoVHKU1, the incidence of all betacoronaviruses could
decline and even virtually disappear.
5. Low levels of cross immunity from the other betacoronaviruses against SARS-CoV-2 could make
SARS-CoV-2 appear to die out [49], only to resurge
after a few years (possibly in 2025).
Therefore, longitudinal serological studies are urgently
needed to determine the duration of immunity to
SARS-CoV-2.[49] In addition, even if the outbreak appears to die out after this first pandemic wave, SARSCoV-2 surveillance should be maintained.
SARS-CoV-2 evolves in vivo after infection, promoting virulence, infectivity, and transmissibility:
By metatranscriptome sequencing of the genomes of
SARS-CoV-2 samples in the current pandemic, the
intra-host variants per individual patients ranged from
0 to 5 with a median number of 4, suggesting a high
evolution rate of the virus.[50] As with other RNA
viruses, SARS-CoV-2 undergoes a strong immunologic
pressure in humans, and may thus accumulate mutations that could result in changes in viral virulence, infectivity, drug resistance and transmissibility to outmaneuver the immune system.[51, 52] The mutation rate
of SARS-CoV-2 is yet unclear, but it is suggested to be at
the same order of magnitude (0.80-2.38×10-3 nucleotide
substitution per site per year) in SARS-CoV.[53] Observation of shared intra-host variants among different
individuals implied the possibility of adaptive evolution of the virus in patients, which could potentially
affect the antigenicity, virulence, and infectivity of the
virus.[52] Similarly, mutations in the RNA-dependentRNA-polymerase (RdRp) gene (nsp12) were reported
in isolates from patients in North America, England
and Italy. This suggests that the virus is evolving,
with potential effects on antiviral drugs targeting the
RdRp.[54] Roman et al. reported independent virus
replication by consistent detection of sequence-distinct
virus populations from the throat and lung samples of
the same patient, thereby substantiating the evolution
of quasi-species. [22] Thus, the SARS-CoV-2 genome
in patients could be highly diverse, as also observed
in other RNA viruses such as HIV with circulating recombinant forms. The high diversity could potentially
9
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increase the fitness of the viral population, making the
elimination difficult.
Conjunctival and conjunctival discharges (or tears)
are potential sources of exposure and contamination:
COVID-19 may be confusing, as it mimics conjunctivitis associated with Adenovirus infection. Recent findings indicated that SARS-CoV-2 infection might present
ocular signs such as photophobia, irritation, conjunctival infection, and watery discharge, which are potential
sources of contamination and infection in about 1-2%
of COVID-19 cases.[55, 56] Therefore, extreme caution
is recommended in ocular discharge transmission and
contraction of COVID-19.
Weaknesses of the Severe Acute Respiratory Syndrome Coronavirus 2
Weaknesses are the characteristics that places the virus
at a disadvantage, relative to the host and the environment. The virus weaknesses detract it from its ability to
attain the core goal, and influence its infectivity, replication, and establishment. Essentially, the attributes of
SARS-CoV-2 that present as “Achilles’ heel” and targets
for elimination (Table 1) are as follows.
Angiotensin-converting enzyme 2 (ACE2) is the sole
receptor for Spike protein of the emergent SARS–
CoV-2: So far, three membrane exopeptidases—
Dipeptidyl peptidase-4 (DPP4), ACE2, and Aminopeptidase N (APN)—have been identified as entry receptors for human-infecting coronaviruses.[57] Among
these cellular receptors, the angiotesin-converting enzyme 2 (ACE2) is the most potent and specific for
SARS-CoV-2 [58], although research is ongoing about
the use of basigin (CD147) as a novel route by SARSCoV-2 to also assist in host cell entry. ACE2 entry is
lineage B clade 1 specific. Studies have shown that protease treatment only enhanced entry of clade 1 RBDs on
cells expressing human ACE2, but not human DPP4 or
APN.[59] The requirement for this indispensable receptors renders the virus vulnerable to molecules or neutralising antibodies that would block acess to the ACE2
protein or that will coat the S1 domain of the viral ligand, thereby preventing attachment.[60]
Host protease processing during viral entry is a significant barrier for several lineage B viruses: For betacoronaviruses, a single region of the spike protein
called the receptor-binding domain (RBD) mediates the
interaction with the host-cell receptor. After binding
the receptor, a nearby host protease cleaves the spike
that releases the spike fusion peptide, thereby facilitating virus entry.[60, 61] The RBD of lineage B betacoronaviruses is a single, continuous domain that contains
all of the structural information necessary to interact
with the host receptor. Consequently, synthetic antiviral drugs that will bind a fusion protein and prevent
its elaboration, such as a protease inhibitor, to prevent
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cleavage by the protease and elicit abortive infection,
such as in oseltamivir (influenza antiviral drug) will be
of great value.
Low basic reproduction number (R0 ) of 3.8: The
SARS-CoV-2 is a highly contagious virus (although
much less than measles) and one of the currently
known most infectious human viruses to which there
is no vaccine. However, it has a low reproduction rate
compared to MERS-CoV and Ebola virus. The current
estimates of the basic reproduction number (the number of people that 1 infected person can infect during
its infectious period, R0 ) are between 1.4 and 3.77 persons.[62] This means that each infection from the virus
is expected to result in 1.4 to 3.8 new infections in an
unexposed population, when no preventive measures
are taken.
SARS-CoV-2 critically requires Porphyrin to inhibit
human heme metabolism: Research literature shows
that SARS-CoV-2 is dependent on porphyrins, thereby
suggesting that it may have originated from an ancient virus. As the virus’ ORF8 and surface glycoprotein binds to the porphyrin, the orf1ab, ORF10, and
ORF3a proteins coordinately attacks the heme on the
1-beta chain of hemoglobin to dissociate the iron at
the same time, to form and capture the porphyrin.
The attacks reduce hemoglobin levels that carry oxygen and carbon dioxide. Consequently, the pneumocytes have extremely intense poisoning and inflammation due to the inability to exchange carbon dioxide
and oxygen, leading to ground-glass-opacification of
the lungs, inhibition of human heme metabolism and
eventual disease.[63] Stemming from this requirement,
to effectively relieve the symptoms of respiratory distress, chloroquine has been found to prevent orf1ab,
ORF3a, and ORF10 in attacking the heme, thereby preventing availability of the porphyrin and as well inhibit
the ORF8 and surface glycoproteins from binding to
porphyrins.[63] In addition, presence of high level of
glycated hemoglobin or deoxyhemoglobin (a combination of hemoglobin and blood glucose) in older people
and diabetics is another reason for the high infection
rate in those groups of patients.
Opportunities for the Severe Acute Respiratory Syndrome
Coronavirus 2
Opportunities are the chances to make greater gains in
the environment, that is, external attractive factors that
represent the reason for SARS-CoV-2 to exist, infect and
spread. Opportunities arise when the virus can take
benefit of conditions in its environment to infect and
execute strategies that enables it to become established
and spread. The various host and environmental factors (Table 1) harnessed for infection by SARS-CoV-2
are as follows.
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Several important organs in the human body express host cellular receptors for SARS-CoV-2 infection: SARS-CoV-2 selectively targets the ACE2 proteins that are constitutively expressed by several important organs in human body. Most importantly, different levels of ACE2 receptor expression exist in the
colon, gall bladder, heart, kidney, epididymis, breast,
ovary, lungs, prostate, esophagus, tongue, liver, pancreas, and cerebellum. These present opportunities for
the virus to replicate in the target sites subsequent upon
systemic dissemination of SARS-CoV-2 which may circulate through the blood and then attack ACE2 receptors in the endothelia cells of blood capillaries in the
brain, breaching the blood-brain barrier and invading
neurons. Therefore, all these organs with ACE2 expression are subject to infection with attendant pathological
effects such as disseminated intravascular coagulation
(DIC), olfactory and gustatory perception impairments
and probable long-time neurological dysfunction even
after recovery.[64]
Ease of travel, globalization, and aviation as potentials for global spread: Frequent air travel or road
transport are major risk factors to the global spread of
infectious diseases. It is feasible to visit as many as
three countries in a few hours and spread infectious
pathogens. In contrast to airlines, public trains, buses,
etc., are rarely fitted with high efficiency particulate air
filters (HEPA). It is not only humans that travel: the
International Air Transport Association estimates that
around 80,000 caught wild animals are air freighted
each year; many being placed in holding facilities close
to populated areas whilst in transit.[65] The potential
routes of transmission of infectious agents on board are
mainly by inhalation of droplets nuclei, direct contact
with organic residues, indirect contact with respiratory
secretions and other biological fluid-contaminated surfaces. Adventure touring or ecotourism, international
importation by air and cruise-ship travels have been
documented in the spread of diseases to humans. In
the current SARS-CoV-2 pandemic, many of the cases
outside of China were linked to travels. A particularly
large outbreak occurred among the passengers and
crew of the Diamond Princess cruise ship, where more
than 700 COVID-19 infections were reported during
the Spring Festival transportation peak in China.[66]
Index cases in many African countries were imported
from overseas travelers prior person-to-person transmission and community spread. A cluster of COVID19 outbreaks were also detected in Hawkeys Bay, New
Zealand, that was epidemiologically linked to a Ruby
Pincess cruise ship that sailed on to Australia with
more than 439 cases and 7 deaths. Once the virus is
introduced to a passenger or crew member on board,
the ship becomes a perfect incubator.
Underlying illnesses, age, gender, smoking, immune
suppression, and blood grouping: Hypertension,
diabetes mellitus, cardiovascular disease and lung can-
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cer are proven conditions that present opportunities to
severe COVID-19 disease. Elderly patients with hypertension, coronary heart disease or diabetes have higher
risk of infection (58% hypertension, 25% heart disease,
44% arrhythmia). Early estimates showed that about
80% of those who died were over the age of 60, and
75% of them had pre-existing health conditions such as
cardiovascular diseases and diabetes.[67] SARS-CoV-2
infects host cells through ACE2 receptor. When the
spike protein binds to ACE2, it reduces ACE2 expression, thereby inducing cellular shedding of the receptor, induction of TNF-a production and viral entry into
host cells. Reduction of ACE2 results in pathophysiology in the lungs, blood pressure, renal function impairment and aldosterone-dependent blood sugar dysregulation which may result in COVID-19-related pneumonia, acute myocardial injury, and chronic damage to the
cardiovascular system. Therefore as the virus replicates
and decreases ACE2 levels, low ACE2 aggravates heart
dysfunction, hypertension, diabetes mellitus, prostate
and lung cancers. Therefore, the trade-off is to either
increase ACE2 synthesis or allow it at the level of the
pathogen. However, ACE2 levels can be increased by
the use of RAS inhibitors as antihypertension therapy
with ACE inhibitors or angiotensin-receptor blockers
but the disease become severe in such compromised
individuals.[67] Furthermore, the ACE2 enzyme is expressed in type II alveolar cells, and some data suggest that Asian males have a large number of ACE2expressing cells in the lungs, which may partially explain the male predominance of COVID-19. However,
other factors such as a higher prevalence of smoking
among men in China may explain the difference in the
sex distribution of the disease. Furthermore, research
found that individuals with blood group A were more
susceptible to SARS-CoV-2 infection than blood group
O. Therefore, emphasis should be considered for protecting people with prior illnesses, older age, smokers,
blood group A, poor hygiene and eating habits.
Rumors and misinformation about origin of SARS–
CoV-2: Conspiracy theories on social media and sensationalist reporting, suggesting that COVID-19 does
not have a natural origin are challenging efforts of outbreak response. Scientists have made concerned statements over the spread of yet unsupported claims that
the new coronavirus, SARS-CoV-2 was created and
leaked from a laboratory in Wuhan, China. Spread
of misinformation and conspiracy theories have generated panic and mistrust among the general public, diverted attention away from the outbreak response, and impeded the activities of health-care workers. Researchers from multiple countries have published and analyzed genomes of SARS-CoV-2, and they
overwhelmingly concluded that this Coronavirus originated in wildlife. On March 17, 2020, scientists reported that the novel SARS-CoV-2 virus originated naturally, and is not a laboratory construct or a purposefully manipulated virus.[35, 68]
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Knowledge is yet evolving on the underlying
pathogenic mechanisms of SARS-CoV-2: As an
emerging pathogen scientists are still in the course of
understanding the underlying pathogenic mechanisms
of SARS-CoV-2.[69] In-depth knowledge will reveal
more targets for better therapy of COVID-19.
Potential silent transmission via blood and blood
products: SARS-CoV-2 was initially isolated in samples of bronchoalveolar lavage fluid and viral RNA
has thereafter been detected in nasopharyngeal and
throat swabs as well as in serum, blood, rectal swabs,
saliva, urine, and stool.[70, 71] SARS-CoV-2 is a respiratory pathogen with inherent ability to disseminate via
plasma or serum. This will impact negatively on substances of human origin (SoHo). While it seems that
the risk of SARS-CoV-2 transmission through SoHO is
very low, uncertainties about viraemia during the incubation period, during an asymptomatic course of infection, or after symptom resolution continue to be of concern in relation to the safety of SoHO. Therefore, a theoretical risk of transmission of Coronaviruses through
the transfusion of labile blood products is emphasized
as a small percentage of blood samples had positive
PCR test results, suggesting that infection sometimes
may be systemic.[72] Therefore matters arising from
these involve the inclusion of screening for SARS-CoV2 in potential blood donors or virus inactivation and removal in blood products or plasma derivatives before
transfusion or in organ donor and transplantation.
No vaccine has yet been approved to treat human COVID-19: Several options can be envisaged
to control or prevent emerging infections of SARSCoV-2, including vaccines, monoclonal antibodies,
oligonucleotide-based therapies, peptides, interferon
therapies and small-molecule drugs. The magnitude of
the current pandemic of COVID-19 and the likelihood
of future human exposures, underscores the necessity
for pre- and post-exposure therapeutics.[73] Historically, vaccination is the best option in controlling viral diseases when epidemics refuse to self-attenuate.
Therefore, the absence of proven vaccines constitutes
an opportunity for the virus to deride the host. In
developing a vaccine against the disease, inactivated
or attenuated virus particle-based preparation is advisable. This can be achieved by large-scale, regulated laboratory culture of SARS-CoV-2 in a BSL-4 facility and
then inactivated by either UV light, formaldehyde or
β-propiolactone. Alternatively, the process to attenuate by several passages and carefully screen the serially propagated viruses for competent immunogenicity and reduced pathogenesis (induced minimal lung
injury, diminished limited neutrophil influx, and increased anti-inflammatory cytokine expressions) compared with the wild-type virus would also prove viable.[74] However, new interventions are likely to require months to develop but it is hoped that as soon as
other FDA approved drug (in addition to Remdesivir)
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or vaccine is found, the rage of the virus would be curtailed.
Confounding pattern of signs and symptoms with
common diseases complicate diagnosis: Variability
of clinical presentations complicate early detection and
management of COVID-19 as it mimicks the presentation of other common respiratory diseases. Early signs
of SARS-CoV-2 infection are nonspecific and mimicks
other acute respiratory illnesses such as RSV, SARSCoV, Influenza, MERS-CoV and even typhoid fever.
In patients with COVID-19, blood tests typically show
leukopenia and lymphopenia and most chest computed tomography scans show ground-glass opacities and consolidation with bilateral lung involvement.
These characteristics are also shared by influenza A
and other respiratory viruses.[67, 75] Mild and presymptomatic cases might easily remain undetected, especially during the influenza season when respiratory
symptoms are common.[76] COVID-19 is characterized by sudden onset of fever (>390C), chills, fatigue,
exhaustion, sore throat, headache, and joint/muscle
aches. Late signs are asphyxiation, pneumonia, kidney failure, septic shock, and death.[8] The major difference between SARS-CoV-2 and her predecessors is
that this virus symptomatically elicits dry cough and
rarely produces rhinorrhea in those infected, which are
common in MERS and SARS cases. Co-infection of
SARS-CoV-2 and influenza A virus has been reported,
thereby demonstrating additional challenges to detection, especially when patients test negative for SARSCoV-2 but positive for another virus. Therefore, in addition to the non-specific symptoms, COVID-19 might
be underdiagnosed because of false-negative results or
co-infection with other respiratory viruses.[77]
Low sensitivity of upper respiratory specimens for
detection of SARS-CoV-2: Diagnosis of COVID-19 is
made mainly on the basis of nucleic acid detection from
nasopharyngeal swabs. A previous report indicated 2
challenges in the diagnosis of COVID-19. First, the sensitivity of tests to detect SARS-CoV-2 from upper respiratory specimens might be insufficient and two, repeated rRT-PCR testing of nasopharyngeal swabs were
usually negative for SARS-CoV-2. In that report, SARSCoV-2 was finally identified by using metagenomic
next-generation sequencing (mNGS) and rRT-PCR of a
bronchoalveolar lavage fluid (BALF) sample. This was
achieved with the persistence of the Clinician because
of the patient’s travel history. Therefore, suitable sputum or BALF specimens are necessary to maximize detection in cases of high clinical suspicion for identifying SARS-CoV-2 because the highest viral loads were
found in sputum with moderate loads in nose-throat
swabs.[72] Testing of specimens from multiple sites
may improve the sensitivity and reduce false-negative
test results.
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Disproportionate or damaging evolution of effective
defenses against the virus (“Cytokine storm”): The
balance and timing of early immune responses to infection play a critical role in determining the outcome of
infections. In some cases, a reaction takes place which
as a whole is labeled a ‘cytokine storm’ that results in
extensive tissue damage. The protagonist of this storm
is interleukin 6 (IL-6), produced by activated leukocytes and acts on a large number of cells and tissues.
The major role of IL-6 is pro-inflammatory, it increases
during inflammatory diseases, infections, autoimmune
disorders, cardiovascular diseases, and some types of
cancer. It is also implicated in the pathogenesis of the
cytokine release syndrome (CRS) that is an acute systemic inflammatory syndrome characterized by fever
and multiple organ dysfunction. Pathological investigation on a COVID-19 patient using peripheral blood
flow cytometric analysis shows hyperactivated CD4
and CD8 T cells with increased concentration of highly
proinflammatory CCR6+ Th17 in CD4 T cells, while the
CD8 T cells were found to harbour high concentrations
of cytotoxic granules and were perforin/granulysin
positive.[78] These imply that overactivation of T cells,
manifested by increase of Th17 and high cytotoxicity of
CD8 T cells, accounts for, in part, the severe immune
injury in the patients.[78] In the case of septic shock in
COVID-19, fatal infection of humans appears to be associated with an elevation or overproduction of antiSARS-CoV-2 pro inflammatory cytokines, TNF-α, and
alveolar macrophages, among others. If SARS-CoV-2
elicits damaging host responses particularly in the elderly, then therapeutic interventions that modify those
responses may help the immune system to control viral
replication and achieve survival.
Potential silent transmission via the fecal-oral route:
Transmission of SARS-CoV-2 by respiratory and extrarespiratory routes may be responsible for the rapid
spread of COVID-19 disease. Prior to respiratory symptoms, many patients reported diarrhea, nausea, vomiting and abdominal discomfort. Immunofluorescent
studies show ACE2 receptors in glandular cells of gastric, duodenal, and rectal epithelia. ACE2 had been reported to be co-localized with TMPRSS2 in absorptive
enterocytes and upper epithelial cells of esophagus.
The first USA confirmed case had a 2 day history of
nausea, vomiting and dry cough while SARS-CoV-2 sequences were detected from the stool.[71] Similarly, in a
previous study, out of 73 patients, 39 tested positive in
the stool (10-78 years of age) for 1-12 days while 17 patients remained positive in the stool even after negative
respiratory samples. The live virus was detected in feces, implying that SARS-CoV-2 may be transmitted by
the fecal-oral route and possibly urine.[41] Therefore,
generation and inhalation of bio-aerosols during flatulence or flushing of the commodes should be avoided
and it may be shown that individuals should not use
the toilet immediately after use by another person.
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Collection, consumption, and trade of wild game:
The index cases of several viral diseases outbreaks have
been more or less directly associated with hunting,
trading, or consumption of bush meat such as monkeys, antelopes, and bats.[79] The SARS, which has
shown its potential in China as a respiratory and gastrointestinal disease, was because of the illegal trade of
wildlife, where an infected masked palm civet (Paguma
larvata) was the culprit for the spread of SARS.[80]
The index case of the initial Coronavirus disease 2019
(COVID-19) were epidemiologically linked to exposure
to Wuhan’s Huanan seafood market in China, where
wild animals are traded and SARS-CoV-2 infections
have been detected in dogs, cats, ferrets, and tiger.[81]
As activities like hunting wild animals and consumption of game meat/ bush meat result in the spread
of zoonotic diseases to humans, about 13,000 pounds
of bushmeat were estimated to be imported into the
UK annually. Therefore, the trade and consumption of
‘bushmeat’ should be highly regulated as these could
serve as sources of outbreak in the respective destinations.
Lack of emergency preparedness, infection control
practices and paucity of health infrastructures: Owing to misplacements of priorities, the dearth of funding, lack of test kits, medical equipment, and accessories (e.g. ventilator), COVID-19 patients were often cared for without the use of personal protective
equipment (face masks, gowns, gloves, goggles, disposable suits, boots, etc). These risks expose health
care providers to infections and hastens the spread
and death in severe cases. Developing economies, especially African, should establish effective and functional public health facilities with the appropriate advanced infrastructure and virologists to cope with
emergency situations and emergency preparedness.
Disease surveillance, intelligence and monitoring in
human and animal populations should be mandatory.
Social mobilization and awareness campaigns should
also be strengthened to dispel dangerous rumors that
encourage spread of dangerous infectious diseases.
Overcrowded institutions, military establishment,
warships, camps, and correctional facilities are potentially vulnerable: As a respiratory virus, the personto-person transmission in crowded, overcrowded, and
confined environments can be exponential. Educational institutions, correctional facilities (prisons)
and military camps are formidable environments for
COVID-19 ravage. COVID-19 infection was first detected on a Naval vessel at sea on March 24, 2020
aboard the US Nuclear Naval ship Aircraft carrier
(Theodore Roosevelt) with reported outbreak among
the crew of more than 4,000 on March 31, 2020 at
Guam.[82] The outbreak was a dangerous phenomena altogether considering the inherent limitation of
space in warships, usually full of weapons, with billion of dollars of equipment, where those positive cases
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jumped exponentially, where fire hazards and nuclear
reactors are present, where quarantine and social distancing is also impossible. Tight quarters in warships
make the virus conducive to spread among large numbers of sailors in a confined space sharing sleeping
quarters, restrooms, workspaces, and mess hall, with
potential susceptibility to reinfection even after recovery. To avert unwarranted spread of COVID-19 in
prison facilities of Nigeria, Indonesia and several other
countries, some inmates were set free by the Government.
Threats to the Severe Acute Respiratory Syndrome Coronavirus 2
Threats are external elements in the environment that
could cause trouble for SARS-CoV-2. That is, external factors, which make the virus vulnerable, beyond
the pathogen’s control, which could place the virus’
mission or operations at risk. Essentially, the external
conditions that are inimical to SARS-CoV-2’s establishment, and which may be harnessed for elimination of
the virus as presented in Table 1, include the following.
Prohibition of mass gatherings, prompt hospitalization, isolation, and quarantine: Quarantine is regarded as enforced isolation of areas or individuals
who may be infected. It may involve closure of schools,
markets, worship congregations, relaxation centres,
conferences and sports competitions, as well as total
shutdown of the system or lockdown of countries. In
addition, social/physical distancing, use of face masks,
respiratory etiquete and hand hygiene are milestones
in reducing transmission of the virus. In the implementation of these threats, the ethical and social aspects
should not be overlooked. Required isolation of patients to avoid transmission should not be seen as segregation and palliative measures must be put in place
to avoid revolts.
Prohibition of all wildlife trade to effectively prevent viral prevalence: The pathogens of SARSCoronavirus and SARS-CoV-2 are both derived from
wild animals. Therefore, hunting, selling, and eating
wild animals not only seriously damage the ecosystem,
but also lead to the spread of epidemic diseases.
Repurposing proven Antimalarial/Antiviral/ anti-inflammatory drugs: Small-molecule agents for treating other human diseases may modulate the virus–
host interactions of SARS-CoV-2. A number of proven
drugs against some diseases are being tested with the
aim of using such to treat COVID-19. Some of these
drugs include remdesivir first developed for Ebola
virus treatment (is now approved by the FDA for
COVID-19); interferon alfa-2b currently used for Hepatitis C with efficacy in animal models against MERSCoV; combination of lopinavir and ritonavir (Kaletra) for HIV-AIDS; favipiravir for Influenza; sarilumab;
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chloroquine and azithromycin are now being tested.[9]
Chloroquine, an approved immune modulator has
been shown to demonstrate inhibitory effects against
SARS-CoV-2 (EC50 =1.13 µM in Vero E6 cells) and evaluation in an open-label clinical trials with COVID19 patients was promising, although an observational
study did not show a benefit.[83-85] With EC50 of
1.13 µmol/L and selectivity index (SI) greater than 88,
chloroquine can effectively inhibit pH dependent endocytosis of SARS-CoV-2 in the cell level as chloroquine
phosphate turns into chloroquine in the body and target the virus’ Nsp3b or E-channel to play therapeutic
effect.[84] Darunavir is an HIV-1 protease inhibitor that
selectively inhibits the cleavage of HIV-encoded GagPol polyprotein in virally infected cells, thereby preventing the formation of mature infectious virus particles. At a concentration of 300 µmol/L, darunavir can
significantly inhibit virus replication while the docking
results showed that the possible targets were Nsp3c,
PLpro, E-channel or spike proteins.[86] Umefenovir
(Arbidol hydrochloride) is a broad-spectrum anti-viral
drug, mainly for the treatment of influenza A and B
viruses, but effective against SARS-CoV and MERSCoV. Arbidol blocks virus replication by inhibiting the
fusion of the lipid membrane of the virus with the
host cells and effectively inhibited Coronavirus up to 60
times at a concentration of 10–30 µmol/L, thereby preventing the virus’s pathological effects on cells while
the docking results with the possible drug targets of the
SARS-CoV-2 showed interaction with Nsp7 Nsp8 complex, Nsp14, Nsp15, E-channel, or the spike.[86] Considering the challenges with vaccine development, it is
pertinent to consider further research into exploiting a
shift from the current paradigm of ‘profitable Pharma
model’ in medicine to a worldwide integrative /alternative / holistic medical practitioners “in the field” for
their experiences in treating otherwise difficult to treat
infections, and a fair review for consideration of traditional, complementary and alternative drugs.
Deployment of rapid laboratory equipment and procedures for prompt detection (ELISA, Western Blot,
PCR): A number of diagnostics and techniques are
currently available for laboratory diagnosis of COVID19. Acute infection is diagnosed by RT-PCR tests to
detect viral antigens. These tests can be positive from
day 3 to 14 days of infection. These technologies and
personnel should be made available for use. Development and deployment of Rapid point of care diagnostics (such as Immunochromatographic EIA kits) will
help in overcoming challenges of weak surveillance.
This will also facilitate testing, and retesting for decisions on isolation, quarantine, treatment, and discharge
as appropriate.
Active contact tracing and monitoring: Contact tracing involves finding everyone who had contact with infected individuals and watching / monitoring for signs
of illness for 21 days, usually 14 days. Contacts in-
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clude close, casual, and distant. If any of the contacts
comes down with the ailment, they should be isolated,
tested, and treated. The process is then repeated by
tracing the contacts’ contacts.[87] In respect of Ship,
buses or air travels, as direct contact is the main route of
transmission for COVID-19, only the passengers who
were seated in direct proximity to the index passenger
should be included in the trace-back, i.e. only passengers who were one seat away from the index case (±1
seat in all directions) should be traced back. If the index
case occupied an aisle seat, the three passengers seated
directly across the aisle from the index case should also
be traced back, as in cases of other virulent viruses.[88]
Appropriate burial practices according to international best practices: To avoid excessive manipulation of the body, embalming is not recommended. People who have died from COVID-19 can be buried or
cremated only as a matter of cultural choice, available resources, and national and local requirements
that may dictate the handling and disposition of the remains.[89] Health care workers, mortuary staff or families, and traditional burial attendants (e.g. family member or religious leader) preparing the deceased (e.g.
washing, cleaning or dressing body, tidying hair, trimming nails or shaving) should wear appropriate PPE
according to standard precautions (gloves, impermeable disposable gown [or disposable gown with impermeable apron], medical mask, eye protection including the use of face shield or goggles) for any activity that may involve splashing or leakage of bodily
fluids.[89] Anyone who has assisted in preparing the
body should thoroughly wash their hands with soap
and water when finished. Family and friends should
reduce their exposure as much as possible and may
view the body after it has been prepared for burial,
in accordance with customs at a minimum distance
of 1 m. They should not touch or kiss the body and
should wash hands thoroughly with soap and water
after the viewing. Children, older people (>60 years
old), and anyone with underlying illnesses (such as
respiratory illness, heart disease, diabetes, or compromised immune systems) should not directly interact
with the body. Burials should take place in a timely
manner with limited number of participants, in accordance with local practices. Participants should observe
physical distancing at all times, plus respiratory etiquette, and hand hygiene. Those tasked with placing
the body in the grave, or the funeral pyre, should wear
gloves and wash hands with soap and water after removal of the gloves once the burial is complete. Funeral ceremonies should be postponed, as much as possible, until the end of the epidemic. The belongings
of the deceased person should be handled with gloves
and cleaned with a detergent followed by disinfection
with a solution of at least 70% ethanol or 0.1% (1000
ppm) hypochlorite.[89]
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Sterilization or disinfection of equipment and safe
disposal of waste: Like other Coronaviruses, SARSCoV-2 is sensitive to ultraviolet rays and heat. It can
be effectively inactivated by lipid solvents including
ether, ethanol, chlorine-containing disinfectant, peroxyacetic acid and chloroform. Appropriate concentration of calcium or sodium hypochlorite (a lipid solvent, an inactivating agent which distrupts the viral
envelope, the ligands, and in effect subsequent attachment and infectivity) is effective to decontaminate the
premises and disinfect equipment and other materials
exposed to biological contamination with SARS-CoV-2.
Patient’ excretions should be disposed of properly, and
hands washed frequently using soap and water for 20
seconds, as well as hand sanitizers containing at least
60% ethanol or 70% isopropanol.[90] Used articles, beddings and linens should be machine washed with laundry detergent and warm water at 60–90°C (140–194°F),
dry and disinfected.[89]
Potential antiviral activities of Coagulation Factor Xa,
IIa (thrombin) and convalescent plasma: Coagulation Factor Xa and IIa (thrombin)were shown to cleave
and activate the Spike S protein of Coronavirus into
S1 and S2 domains, thereby facilitating cellular infectivity.[91] This finding was employed recently by Ai et
al. who identified “Dabigatran” as a possible therapeutic for COVID-19.[39] Similarly, the possible benefit of
dipyridamole (anticoagulant) for COVID-19 was also
reported.[92] Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with SARS, and recovered from
Ebola virus disease was recommended by WHO as an
empirical treatment during Ebola outbreaks while a
protocol for the use of convalescent plasma in the treatment of MERS was established in 2015.[73] Following
these previous successes, these treatment strategies can
also be adapted in the current fight against COVID-19.
Availability of the genome sequences of SARS–
CoV-2: The genome composition and divergence of
the novel coronavirus was determined by sequencing
in mid January in China as well as in Australia, Philipines and USA, while cryo-EM technique has revealed
the atomic structure of the spike protein of SARS-COV2.[93, 94] As of March 2020, 183 genome sequences of
the SARS-COV-2 isolates around the world have been
provided in the GenBank. These rapid achievements
provide information that will specifically help in development of appropriate diagnostic tests, therapeutics,
and vaccine design against the virus.[95]
Global COVID-19 research funding: The outbreak
has prompted WHO and some other major global and
national health organizations to announce the research
on COVID-19 as a priority with dedicating huge funds
for the related investigations. A meeting for the assessment of current knowledge on this viral disease and determining the research directions was held by WHO in
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collaboration with GloPID-R (the Global Research Collaboration for Infectious Disease Preparedness) with
the participation of scientists from various disciplines
and funders from different parts of the world.[96] Individual countries are taking the initiatives in providing fundings for research as well as mitigating the impacts of lockdown and shutdown while philantropists
around the world are donating money, equipment,
reagents, test kits, personal protective equipment, and
so on, to overcome this “millenium enemy against humanity.”

Conclusion
As in any battle, knowing the enemy is a major step for
defeating it. There are still many unknowns about the
emergent SARS-CoV-2. Great efforts are being taken
to elucidate the virus behavior, transmission, biological strenghts, opportunities for infection and other aspects. As a paradigm shift, the SWOT concept can be
adopted to help us as scientists to formulate and apply
strategies that augment our research and enable us to
understand and combat emerging and/or recalcitrant
infectious diseases. This research contributes answers
to some of the questions that borders on exposing the
“Achilles heel” of the virus for interventions in eradication of the COVID-19 pandemic.

Acknowledgements: I gratefully acknowledge the diverse
authors and sources whose publications and materials were
synthesized to generate these analyses. I thank the University of Louisville Journal of Respiratory Infections, the Editors,
ThinkIR and bepress™ for the free publication of this paper.
To God be the glory, the greatest scientist yesterday, today
and forever.

SWOT Analysis of SARS-CoV-2

The identified capacities and gaps presented in this
study are an inexhaustive framework to combat the
SARS-CoV-2 virus and COVID-19. Mankind is dealing
with a major threat to human life on earth, and a transboundary human and animal disease that could easily
be turned into a bioweapon. Committed research communities can and will tap from these findings, in addition to established foundational knowledge, to guide
appropriate responses to the COVID-19 challenges.
It is pertinent to state that SARS-CoV-2 explores its biological strengths, conserves its weaknesses, and exploits host opportunities to decimate human population to the extent that within 5 months, over 310,082
lives have been lost to this virus around the world.
To undermine and overcome the virus, research focus
should be aimed at strategically crushing the strengths
and opportunities that are helpful to SARS-CoV-2 in
achieving the pathogenic objective, while increasing
further the weaknesses of, and threats to the virus that
are harmful to achieving the pathogenic objective.
Research scientists, the academia and the industry should scale up all promising research findings
by holistically harmonising all the identified factors,
putting them into perspective and build more on
threats to the virus.
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